<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl3">
 <label>Table 3</label>
 <caption>
  <p>Overview of key decision points in medical countermeasure development</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th align="left">
     <bold>Description</bold>
    </th>
    <th align="left">
     <bold>Key considerations</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Response tools</td>
    <td align="left">Select a combination of diagnostics, vaccines, and therapeutic products on the basis of the epidemic response and control strategy</td>
    <td align="left">Epidemic or pandemic potential of the pathogen (eg, virulence, latency, pathophysiology); technical feasibility (eg, similarity to known pathogen, antigenic diversity, biomarkers); availability of other public health or epidemic control measures (eg, vector control, social distancing)</td>
   </tr>
   <tr>
    <td align="left">Product strategy</td>
    <td align="left">Generate a product-specific target product profile to define essential product performance specifications</td>
    <td align="left">Indication for use (eg, pre-exposure or post-exposure prophylaxis, suppressive therapy); vaccination strategy and target population (eg, herd 
     <italic>vs</italic> ring vaccination, use in paediatric populations or pregnant women, geographical considerations); durability of protection, product formulation stability and storage, route of administration, production, co-administration or combination therapy
    </td>
   </tr>
   <tr>
    <td align="left">Target selection</td>
    <td align="left">Identify and prioritise potential targets for vaccine and drug candidate development that meet the target product profile</td>
    <td align="left">Understanding of the natural history, biology, pathogenesis, and genetics of the pathogen (eg, viral life cycle, entry mechanisms, hosts, genomic sequence); mechanism of action or immunological response, and product development biomarkers</td>
   </tr>
   <tr>
    <td align="left">Animal model</td>
    <td align="left">Select and develop well-defined and standardised animal models that recapitulate the pathogenesis of human disease to do efficacy studies</td>
    <td align="left">Correlation of animal and human response, ease of use, animal rule requirements; availability, standardisation, and validation of reagents and related assays; toxicology studies or data required for drug repurposing</td>
   </tr>
   <tr>
    <td align="left">Platform selection</td>
    <td align="left">Vaccine type (eg, attenuated and recombinant protein with or without adjuvants), therapeutics (eg, small molecules, antibodies), diagnostics (eg, lateral flow, nucleic acid technology)</td>
    <td align="left">Safety profile, speed of development, complexity, ability to culture pathogen, immunological response (eg, humoral 
     <italic>vs</italic> cellular, duration); availability of verification specimens
    </td>
   </tr>
   <tr>
    <td align="left">Manufacturing</td>
    <td align="left">Select suitable platform for manufacture of quality product at required scale</td>
    <td align="left">Biocontainment requirements, scalability, available capacity, formulation, dose selection, regulatory requirements for release assay validation, and qualification or validation of good manufacturing practices</td>
   </tr>
   <tr>
    <td align="left">Clinical development plan</td>
    <td align="left">Define clinical trial design (geography, sites, sample size, control groups) including clinical endpoints (survival 
     <italic>vs</italic> disease prevention)
    </td>
    <td align="left">Expertise of clinical trial sites, capacity, disease incidence or epidemiology studies; established infrastructure (including patient recruitment and enrolment, data collection and management); coordination between operational (ie, outbreak response) and research groups</td>
   </tr>
   <tr>
    <td align="left">Manufacturing partner</td>
    <td align="left">Identify qualified partners with the required manufacturing capabilities of good manufacturing practices and the capacity to meet product specifications</td>
    <td align="left">Technology transfer plan, requisite infrastructure (capital equipment, talent, vendor support), access to raw materials, fill-finish capability</td>
   </tr>
   <tr>
    <td align="left">Delivery</td>
    <td align="left">Define product access and delivery methods across the supply chain</td>
    <td align="left">Supply chain requirements (cold chain or thermostability); in-country operations, transfer and import or export agreements; means of dissemination (eg, fixed posts 
     <italic>vs</italic> house-to-house campaigns)
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
